Novo Nordisk AS's total inventories for the quarter that ended in Mar. 2026 was MXN143,228 Mil. Novo Nordisk AS's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was MXN141,655 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Novo Nordisk AS's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was MXN-155.20.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Novo Nordisk AS's Days Inventory for the
three
months ended in Mar. 2026 was 340.81.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Novo Nordisk AS's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.27.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Novo Nordisk AS's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.52.
Novo Nordisk AS (MEX:NOVOBN) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Novo Nordisk AS's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Novo Nordisk AS's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Novo Nordisk AS Total Inventories Related Terms
Novo Nordisk AS Total Inventories Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of MXN143,228 Mil mean?
Novo Nordisk AS (MEX:NOVOBN) has a Total Inventories of MXN143,228 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Total Inventories too high?
Novo Nordisk AS's current Total Inventories is MXN143,228 Mil. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Total Inventories compare to LLY and JNJ?
Novo Nordisk AS's Total Inventories of MXN143,228 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Novo Nordisk AS and its competitors. Novo Nordisk AS's current Total Inventories is MXN143,228 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Total Inventories is MXN143,228 Mil. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Total Inventories is MXN143,228 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NOVOBN:
Total Inventories: MXN143,228 Mil
GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score
Get the complete analysis for MEX:NOVOBN
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NOVOBN has been successfully added to your 
